Kamaptive Technology Licensing & Partnership update

Creo Medical has today provided an update on its Kamaptive Technology (“Kamaptive”) licensing and partnership programme.


The Company has entered into non-binding heads of terms (the “HoTs”) with a number of parties which relate to the Company’s SpydrBlade, Cool Plasma and MicroBlate technologies.  As outlined previously, Creo is developing its business through a three-tiered Build, Buy and Partner strategy.  Having already demonstrated execution on the Build and Buy elements, the Partner strategy aims to create shareholder value through granting third-party access to Creo’s advanced energy technology in markets adjacent to those where the Company is already operating. This includes fields such as laparoscopic surgery, robotically assisted surgery, and non-thermal plasma sterilisation.  


The Company considers these HoTs, to be a key milestone in achieving its stated goal of licensing its technology to established, multi-national partners and is in line with the strategy set out at the time of its fundraising last year. Negotiations on final legally binding agreements are underway and Creo is mobilising resources to deliver against its obligations.  The Company will update shareholders as appropriate in due course.


Creo continues to receive considerable interest in its technology.  The Company believes that the parallel applications of its technology provide significant opportunities for growth, and a number of pipeline opportunities under discussion enables Creo to exploit its significant IP portfolio.  With the right partners, the Company believes that Creo’s Kamaptive Technology has the potential to accelerate the inevitable change in the way that patients are cared for and treated and, most importantly, improve patient outcomes.

Craig Gulliford, Chief Executive Officer of Creo, commented:

The signing of heads of terms, and the pipeline of interest we have, demonstrates the potential that our technology has to extend into adjacent markets and to generate significant additional, long term, revenue streams. We are mindful to ensure that potential partners share Creo’s values and the commitment to improving patient outcomes, as well as identifying adjacent markets which are growing and have the potential to provide long term value creation for our shareholders.

About Kamaptive Technology

Creo is developing and commercialising a suite of electrosurgical medical devices, each enabled by the CROMA Advanced Energy platform, powered by Kamaptive. The Group has developed the Kamaptive powered full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions.

Posted 24/01/2022

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

15 May 2024

Full results - Final Results Strong revenue growth and significant commercial progress (9th May 2024)


13 May 2024

Directorate Changes - May 2024


07 May 2024

Creo Medical receives King’s Award for Enterprise in Innovation


02 May 2024

MicroBlate Flex in new clinical trial at Royal Brompton Hospital


24 April 2024

NHS Supply Chain real-world data demonstrates substantial cash savings


19 March 2024

Welsh Labour Leader visits Creo’s facilities


05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi


31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific


10 January 2024

First Use of Speedboat® UltraSlim in Latin America


13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch